Tolvaptan
JYNARQUE, SAMSCA
Vasopressin V2 Receptor Antagonist
NADAC/unit
$21.2475
No Shortage
Tier 1: 145.0%
PA Req: 687.2%
6 Manufacturers
21 ANDAs
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
vs. brand JYNARQUE: Generic saves up to -112% per unit
Generic Manufacturers
ALKEM LABORATORIES LTDAPOTEX INCHETERO LABS LTD UNIT VLUPIN LTDMSN LABORATORIES PRIVATE LTDOTSUKA PHARMACEUTICAL CO LTDPH HEALTH LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.